Concepts (354)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Exercise | 25 | 2023 | 960 | 1.910 |
Why?
|
| Diabetes Mellitus, Type 2 | 14 | 2022 | 730 | 1.730 |
Why?
|
| Transgender Persons | 3 | 2018 | 69 | 1.360 |
Why?
|
| Blood Glucose | 18 | 2018 | 497 | 1.120 |
Why?
|
| Obesity | 10 | 2025 | 1263 | 1.010 |
Why?
|
| Bisexuality | 1 | 2025 | 14 | 0.940 |
Why?
|
| Homosexuality, Female | 1 | 2025 | 22 | 0.930 |
Why?
|
| Sexual and Gender Minorities | 1 | 2025 | 74 | 0.850 |
Why?
|
| Walking | 7 | 2023 | 242 | 0.820 |
Why?
|
| Insulin | 16 | 2018 | 695 | 0.790 |
Why?
|
| Muscle, Skeletal | 11 | 2025 | 768 | 0.770 |
Why?
|
| Exercise Test | 13 | 2023 | 256 | 0.740 |
Why?
|
| Periodicals as Topic | 1 | 2024 | 179 | 0.690 |
Why?
|
| Hypothyroidism | 1 | 2021 | 43 | 0.670 |
Why?
|
| Postprandial Period | 2 | 2018 | 20 | 0.610 |
Why?
|
| Transsexualism | 2 | 2013 | 14 | 0.590 |
Why?
|
| Mentors | 1 | 2020 | 120 | 0.590 |
Why?
|
| Monitoring, Ambulatory | 2 | 2009 | 56 | 0.550 |
Why?
|
| Male | 56 | 2025 | 30894 | 0.550 |
Why?
|
| Humans | 67 | 2025 | 64908 | 0.520 |
Why?
|
| Hormone Replacement Therapy | 1 | 2017 | 30 | 0.520 |
Why?
|
| Female | 51 | 2025 | 33853 | 0.510 |
Why?
|
| Gait | 4 | 2023 | 121 | 0.480 |
Why?
|
| Community Health Workers | 1 | 2016 | 41 | 0.480 |
Why?
|
| Hypoglycemic Agents | 6 | 2013 | 225 | 0.470 |
Why?
|
| Professional Competence | 1 | 2016 | 92 | 0.460 |
Why?
|
| Needs Assessment | 1 | 2016 | 201 | 0.450 |
Why?
|
| Adult | 35 | 2025 | 17282 | 0.430 |
Why?
|
| Energy Metabolism | 8 | 2010 | 394 | 0.400 |
Why?
|
| Glycogen | 4 | 2007 | 40 | 0.380 |
Why?
|
| Metformin | 5 | 2013 | 75 | 0.380 |
Why?
|
| Middle Aged | 28 | 2025 | 18166 | 0.370 |
Why?
|
| Weight Loss | 2 | 2013 | 275 | 0.370 |
Why?
|
| Self Care | 3 | 2008 | 214 | 0.370 |
Why?
|
| Glucose | 7 | 2008 | 476 | 0.360 |
Why?
|
| Diabetes Mellitus | 4 | 2011 | 554 | 0.360 |
Why?
|
| Cultural Characteristics | 2 | 2003 | 38 | 0.340 |
Why?
|
| Nitric Oxide Synthase | 1 | 2009 | 45 | 0.310 |
Why?
|
| Urban Population | 4 | 2003 | 201 | 0.310 |
Why?
|
| Young Adult | 13 | 2025 | 4784 | 0.300 |
Why?
|
| Dexamethasone | 3 | 2007 | 211 | 0.300 |
Why?
|
| Saphenous Vein | 1 | 2009 | 51 | 0.300 |
Why?
|
| Myocardial Revascularization | 1 | 2009 | 78 | 0.300 |
Why?
|
| Metabolic Equivalent | 4 | 2023 | 13 | 0.290 |
Why?
|
| Insulin Resistance | 7 | 2011 | 413 | 0.290 |
Why?
|
| Attitude to Health | 4 | 2000 | 296 | 0.290 |
Why?
|
| Gastric Bypass | 1 | 2009 | 69 | 0.280 |
Why?
|
| Muscle Contraction | 3 | 2015 | 202 | 0.270 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2016 | 214 | 0.270 |
Why?
|
| Obesity, Morbid | 1 | 2009 | 93 | 0.270 |
Why?
|
| Glycogen Synthase | 1 | 2007 | 4 | 0.260 |
Why?
|
| Cardiovascular Diseases | 2 | 2013 | 862 | 0.260 |
Why?
|
| Body Mass Index | 3 | 2025 | 888 | 0.240 |
Why?
|
| Gene Expression Regulation | 3 | 2011 | 1634 | 0.240 |
Why?
|
| Heterosexuality | 1 | 2025 | 10 | 0.240 |
Why?
|
| United States | 3 | 2025 | 8067 | 0.240 |
Why?
|
| Androgens | 1 | 2005 | 66 | 0.220 |
Why?
|
| Acidosis | 1 | 2025 | 27 | 0.220 |
Why?
|
| Aged | 17 | 2025 | 14872 | 0.220 |
Why?
|
| Oxygen Consumption | 5 | 2010 | 213 | 0.220 |
Why?
|
| Nutrition Surveys | 1 | 2025 | 147 | 0.220 |
Why?
|
| Testosterone | 1 | 2005 | 128 | 0.220 |
Why?
|
| Muscle Fatigue | 1 | 2025 | 48 | 0.210 |
Why?
|
| Correspondence as Topic | 1 | 2024 | 11 | 0.210 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2023 | 8 | 0.200 |
Why?
|
| Editorial Policies | 1 | 2024 | 54 | 0.200 |
Why?
|
| Acceleration | 1 | 2023 | 35 | 0.200 |
Why?
|
| Heptanoic Acids | 2 | 2013 | 22 | 0.200 |
Why?
|
| Pyrroles | 2 | 2013 | 49 | 0.190 |
Why?
|
| Running | 1 | 2023 | 84 | 0.190 |
Why?
|
| Diet, Diabetic | 2 | 2000 | 13 | 0.190 |
Why?
|
| Myocarditis | 1 | 2023 | 71 | 0.180 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2022 | 4 | 0.180 |
Why?
|
| Overweight | 2 | 2018 | 256 | 0.180 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 14 | 0.180 |
Why?
|
| Prevalence | 2 | 2025 | 1437 | 0.180 |
Why?
|
| Actins | 1 | 2023 | 262 | 0.180 |
Why?
|
| Aging | 2 | 2025 | 761 | 0.170 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 2697 | 0.170 |
Why?
|
| Physical Exertion | 2 | 2019 | 80 | 0.170 |
Why?
|
| Hyperglycemia | 2 | 2018 | 104 | 0.170 |
Why?
|
| NF-kappa B | 2 | 2013 | 436 | 0.160 |
Why?
|
| Monosaccharide Transport Proteins | 2 | 1998 | 43 | 0.160 |
Why?
|
| Coronary Artery Bypass | 3 | 2011 | 292 | 0.160 |
Why?
|
| Thyroid Diseases | 1 | 2020 | 30 | 0.160 |
Why?
|
| Carbohydrate Metabolism | 5 | 2010 | 49 | 0.150 |
Why?
|
| Motor Activity | 2 | 2016 | 347 | 0.150 |
Why?
|
| Pilot Projects | 2 | 2023 | 1010 | 0.150 |
Why?
|
| Metabolic Syndrome | 2 | 2013 | 146 | 0.150 |
Why?
|
| Universities | 1 | 2000 | 168 | 0.150 |
Why?
|
| Muscle Strength | 3 | 2013 | 40 | 0.150 |
Why?
|
| Energy Intake | 3 | 2008 | 173 | 0.150 |
Why?
|
| Patient Education as Topic | 3 | 2009 | 481 | 0.150 |
Why?
|
| History, 21st Century | 1 | 2020 | 178 | 0.150 |
Why?
|
| Models, Biological | 3 | 2010 | 1204 | 0.140 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2009 | 62 | 0.140 |
Why?
|
| History, 20th Century | 1 | 2020 | 232 | 0.140 |
Why?
|
| Hexoses | 1 | 1998 | 3 | 0.140 |
Why?
|
| Motor Skills | 1 | 2018 | 61 | 0.140 |
Why?
|
| Blood Pressure | 2 | 2018 | 525 | 0.140 |
Why?
|
| Students | 1 | 2000 | 226 | 0.140 |
Why?
|
| Microcirculation | 1 | 1998 | 59 | 0.140 |
Why?
|
| Dietary Carbohydrates | 2 | 2008 | 62 | 0.140 |
Why?
|
| Massachusetts | 4 | 2016 | 2143 | 0.140 |
Why?
|
| Diabetes Complications | 3 | 2011 | 106 | 0.130 |
Why?
|
| Empathy | 1 | 2018 | 70 | 0.130 |
Why?
|
| Emotional Intelligence | 1 | 2017 | 4 | 0.130 |
Why?
|
| Reading | 1 | 2018 | 94 | 0.130 |
Why?
|
| Fatty Acids | 1 | 2018 | 197 | 0.130 |
Why?
|
| Comprehension | 1 | 2018 | 138 | 0.130 |
Why?
|
| Vitamin D | 1 | 2018 | 139 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2020 | 270 | 0.130 |
Why?
|
| Cerebrovascular Circulation | 1 | 1998 | 183 | 0.130 |
Why?
|
| Double-Blind Method | 6 | 2016 | 740 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2009 | 581 | 0.120 |
Why?
|
| Creatine Kinase | 2 | 2013 | 42 | 0.120 |
Why?
|
| Sucrose | 1 | 1996 | 29 | 0.120 |
Why?
|
| Professional-Patient Relations | 1 | 2017 | 127 | 0.120 |
Why?
|
| Self-Assessment | 1 | 2016 | 59 | 0.120 |
Why?
|
| Muscle Proteins | 1 | 1996 | 117 | 0.120 |
Why?
|
| Anticholesteremic Agents | 1 | 2016 | 35 | 0.120 |
Why?
|
| Biomarkers | 4 | 2011 | 1471 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2007 | 623 | 0.120 |
Why?
|
| Counseling | 2 | 2009 | 375 | 0.120 |
Why?
|
| Pain | 2 | 2009 | 398 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2000 | 630 | 0.110 |
Why?
|
| Health Status | 1 | 1998 | 448 | 0.110 |
Why?
|
| Rats | 4 | 2007 | 1996 | 0.110 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1994 | 22 | 0.110 |
Why?
|
| Health Behavior | 1 | 1998 | 482 | 0.100 |
Why?
|
| Cross-Over Studies | 5 | 2018 | 164 | 0.100 |
Why?
|
| Adaptation, Physiological | 1 | 2015 | 130 | 0.100 |
Why?
|
| Heart Rate | 4 | 2013 | 331 | 0.100 |
Why?
|
| Extracellular Matrix | 1 | 2015 | 148 | 0.100 |
Why?
|
| Fatty Acids, Nonesterified | 3 | 2009 | 52 | 0.100 |
Why?
|
| Analysis of Variance | 3 | 2010 | 604 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2009 | 726 | 0.100 |
Why?
|
| Musculoskeletal Pain | 1 | 2012 | 26 | 0.090 |
Why?
|
| C-Reactive Protein | 2 | 2013 | 168 | 0.090 |
Why?
|
| Cardioplegic Solutions | 2 | 2004 | 9 | 0.090 |
Why?
|
| Estrogens | 2 | 2023 | 116 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 408 | 0.090 |
Why?
|
| Glucose Intolerance | 1 | 2013 | 90 | 0.090 |
Why?
|
| Linear Models | 2 | 2010 | 406 | 0.090 |
Why?
|
| ROC Curve | 2 | 2023 | 292 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2017 | 2092 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2022 | 5576 | 0.090 |
Why?
|
| Pericytes | 1 | 2011 | 17 | 0.090 |
Why?
|
| Primary Health Care | 1 | 2017 | 718 | 0.090 |
Why?
|
| Body Weight | 2 | 2007 | 375 | 0.090 |
Why?
|
| Prediabetic State | 1 | 2011 | 53 | 0.080 |
Why?
|
| Rest | 3 | 2019 | 46 | 0.080 |
Why?
|
| Graves Disease | 1 | 2011 | 16 | 0.080 |
Why?
|
| Diabetic Angiopathies | 2 | 1990 | 29 | 0.080 |
Why?
|
| Thyroid Gland | 2 | 2007 | 83 | 0.080 |
Why?
|
| Parathyroid Hormone | 1 | 2010 | 44 | 0.080 |
Why?
|
| Bicycling | 1 | 2010 | 20 | 0.080 |
Why?
|
| Radiation Dosage | 1 | 2011 | 140 | 0.080 |
Why?
|
| Brain | 1 | 1998 | 1597 | 0.080 |
Why?
|
| Coronary Disease | 2 | 1990 | 246 | 0.080 |
Why?
|
| Cholesterol, LDL | 1 | 2009 | 104 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 214 | 0.070 |
Why?
|
| Pulmonary Gas Exchange | 2 | 2008 | 43 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2009 | 146 | 0.070 |
Why?
|
| Appetite Regulation | 1 | 2008 | 8 | 0.070 |
Why?
|
| Monitoring, Intraoperative | 1 | 2009 | 47 | 0.070 |
Why?
|
| Meta-Analysis as Topic | 1 | 2009 | 78 | 0.070 |
Why?
|
| Hormones | 1 | 2008 | 62 | 0.070 |
Why?
|
| West Indies | 2 | 1998 | 6 | 0.070 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 177 | 0.070 |
Why?
|
| Eating | 1 | 2009 | 138 | 0.070 |
Why?
|
| Educational Status | 1 | 2009 | 277 | 0.070 |
Why?
|
| Psychotropic Drugs | 1 | 2008 | 81 | 0.070 |
Why?
|
| Diet | 3 | 2008 | 534 | 0.070 |
Why?
|
| Hyperinsulinism | 2 | 1998 | 26 | 0.070 |
Why?
|
| Treatment Outcome | 7 | 2013 | 5774 | 0.060 |
Why?
|
| Perception | 1 | 2008 | 181 | 0.060 |
Why?
|
| Calcium | 1 | 2010 | 583 | 0.060 |
Why?
|
| Glucose Clamp Technique | 3 | 2011 | 57 | 0.060 |
Why?
|
| Potassium | 2 | 2004 | 97 | 0.060 |
Why?
|
| Time Factors | 6 | 2011 | 3757 | 0.060 |
Why?
|
| Hormone Antagonists | 1 | 2005 | 12 | 0.060 |
Why?
|
| Lipid Peroxidation | 1 | 2005 | 67 | 0.060 |
Why?
|
| Deoxyadenine Nucleotides | 1 | 2025 | 3 | 0.060 |
Why?
|
| Calorimetry, Indirect | 2 | 2019 | 32 | 0.060 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2005 | 90 | 0.060 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2009 | 269 | 0.060 |
Why?
|
| Qualitative Research | 1 | 2009 | 744 | 0.060 |
Why?
|
| Elasticity | 1 | 2025 | 45 | 0.060 |
Why?
|
| Viscosity | 1 | 2025 | 59 | 0.060 |
Why?
|
| Myosin Heavy Chains | 1 | 2025 | 46 | 0.060 |
Why?
|
| Drug Costs | 1 | 2005 | 55 | 0.050 |
Why?
|
| Life Style | 2 | 2011 | 320 | 0.050 |
Why?
|
| Phosphates | 1 | 2025 | 102 | 0.050 |
Why?
|
| Animals | 5 | 2023 | 21339 | 0.050 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2025 | 95 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2005 | 371 | 0.050 |
Why?
|
| Interviews as Topic | 2 | 1998 | 529 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 461 | 0.050 |
Why?
|
| Flutamide | 1 | 2023 | 4 | 0.050 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2023 | 11 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2003 | 2759 | 0.050 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2003 | 2 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2005 | 456 | 0.050 |
Why?
|
| Nutrition Policy | 1 | 2003 | 40 | 0.050 |
Why?
|
| Lipid Metabolism | 3 | 2010 | 224 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2003 | 36 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2005 | 365 | 0.050 |
Why?
|
| Adolescent | 4 | 2010 | 6305 | 0.050 |
Why?
|
| Inflammation | 1 | 2009 | 1191 | 0.050 |
Why?
|
| Walking Speed | 1 | 2022 | 24 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2010 | 610 | 0.050 |
Why?
|
| Oxidation-Reduction | 3 | 2010 | 324 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2003 | 106 | 0.050 |
Why?
|
| Body Composition | 3 | 2008 | 154 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 460 | 0.040 |
Why?
|
| Progesterone | 1 | 2002 | 165 | 0.040 |
Why?
|
| Longevity | 1 | 2022 | 117 | 0.040 |
Why?
|
| Depression | 1 | 2008 | 892 | 0.040 |
Why?
|
| Nutrition Disorders | 1 | 2001 | 7 | 0.040 |
Why?
|
| Homebound Persons | 1 | 2001 | 7 | 0.040 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2000 | 13 | 0.040 |
Why?
|
| Placebos | 2 | 2012 | 73 | 0.040 |
Why?
|
| Poverty | 1 | 2003 | 301 | 0.040 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2011 | 83 | 0.040 |
Why?
|
| Algorithms | 3 | 2011 | 1040 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 434 | 0.040 |
Why?
|
| Thyroid Hormones | 3 | 2008 | 81 | 0.040 |
Why?
|
| Peer Group | 1 | 2000 | 113 | 0.040 |
Why?
|
| Heuristics | 1 | 2019 | 8 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2010 | 149 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 2000 | 286 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2011 | 575 | 0.040 |
Why?
|
| Meals | 1 | 2018 | 27 | 0.040 |
Why?
|
| Nutritional Sciences | 1 | 1998 | 32 | 0.040 |
Why?
|
| Streptozocin | 1 | 1998 | 23 | 0.040 |
Why?
|
| Dietary Sucrose | 1 | 1998 | 24 | 0.030 |
Why?
|
| Glucose Transporter Type 1 | 1 | 1998 | 51 | 0.030 |
Why?
|
| Body Image | 1 | 1998 | 31 | 0.030 |
Why?
|
| Risk Factors | 3 | 2013 | 5407 | 0.030 |
Why?
|
| HIV-1 | 1 | 2003 | 705 | 0.030 |
Why?
|
| Reference Values | 1 | 1998 | 328 | 0.030 |
Why?
|
| Kinetics | 2 | 2011 | 759 | 0.030 |
Why?
|
| Medical Records | 1 | 1998 | 139 | 0.030 |
Why?
|
| Boston | 1 | 1998 | 257 | 0.030 |
Why?
|
| Postoperative Complications | 2 | 2004 | 1313 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 1580 | 0.030 |
Why?
|
| Glucose Transporter Type 4 | 1 | 1996 | 60 | 0.030 |
Why?
|
| Health Surveys | 1 | 1998 | 317 | 0.030 |
Why?
|
| Lactic Acid | 2 | 2010 | 75 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 1996 | 293 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 1998 | 263 | 0.030 |
Why?
|
| Accelerometry | 1 | 2016 | 64 | 0.030 |
Why?
|
| Tenascin | 1 | 2015 | 4 | 0.030 |
Why?
|
| Satellite Cells, Skeletal Muscle | 1 | 2015 | 15 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2000 | 768 | 0.030 |
Why?
|
| Laminin | 1 | 2015 | 81 | 0.030 |
Why?
|
| Caribbean Region | 1 | 1994 | 21 | 0.030 |
Why?
|
| Collagen | 1 | 2015 | 135 | 0.030 |
Why?
|
| Myocardium | 1 | 1996 | 301 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2011 | 3303 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 182 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 1996 | 299 | 0.030 |
Why?
|
| Myalgia | 1 | 2013 | 2 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2015 | 1572 | 0.020 |
Why?
|
| Hypertension | 1 | 2018 | 610 | 0.020 |
Why?
|
| Resistance Training | 1 | 2013 | 22 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2013 | 71 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2012 | 84 | 0.020 |
Why?
|
| Muscles | 1 | 2013 | 179 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 325 | 0.020 |
Why?
|
| Adiposity | 1 | 2013 | 83 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 856 | 0.020 |
Why?
|
| PAX7 Transcription Factor | 1 | 2011 | 9 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2011 | 35 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2011 | 46 | 0.020 |
Why?
|
| Triglycerides | 1 | 2013 | 248 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2011 | 175 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2011 | 25 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 2011 | 58 | 0.020 |
Why?
|
| Radiometry | 1 | 2011 | 39 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2011 | 87 | 0.020 |
Why?
|
| Hypoglycemia | 1 | 2011 | 64 | 0.020 |
Why?
|
| Antigens | 1 | 2011 | 145 | 0.020 |
Why?
|
| Coronary Artery Disease | 2 | 2011 | 322 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 543 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 11113 | 0.020 |
Why?
|
| Ghrelin | 1 | 2008 | 18 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1642 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 2483 | 0.020 |
Why?
|
| DNA | 1 | 2013 | 852 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2010 | 309 | 0.020 |
Why?
|
| Leptin | 1 | 2008 | 88 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2009 | 86 | 0.020 |
Why?
|
| Electron Transport Complex I | 1 | 2008 | 14 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2008 | 121 | 0.020 |
Why?
|
| Anaerobic Threshold | 1 | 2007 | 12 | 0.020 |
Why?
|
| Iodine | 1 | 1988 | 20 | 0.020 |
Why?
|
| Glycerol | 1 | 2007 | 34 | 0.020 |
Why?
|
| Thoracic Surgery | 1 | 2009 | 80 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2007 | 76 | 0.020 |
Why?
|
| Feedback | 1 | 2007 | 91 | 0.020 |
Why?
|
| Homeostasis | 1 | 2010 | 378 | 0.020 |
Why?
|
| Weight Gain | 1 | 2008 | 166 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 962 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2009 | 400 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 1160 | 0.010 |
Why?
|
| Sex Factors | 1 | 2008 | 990 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2005 | 49 | 0.010 |
Why?
|
| Physical Fitness | 1 | 2005 | 93 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2007 | 484 | 0.010 |
Why?
|
| Cardiac Catheterization | 1 | 1987 | 292 | 0.010 |
Why?
|
| Lactates | 1 | 2004 | 29 | 0.010 |
Why?
|
| Cardiotonic Agents | 1 | 2004 | 54 | 0.010 |
Why?
|
| Coronary Stenosis | 1 | 2004 | 41 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2003 | 65 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 2003 | 35 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2003 | 92 | 0.010 |
Why?
|
| Liver | 1 | 2007 | 867 | 0.010 |
Why?
|
| Probability | 1 | 2003 | 168 | 0.010 |
Why?
|
| Surgical Wound Infection | 1 | 2004 | 125 | 0.010 |
Why?
|
| Epinephrine | 1 | 2002 | 45 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 295 | 0.010 |
Why?
|
| Menstrual Cycle | 1 | 2002 | 83 | 0.010 |
Why?
|
| Norepinephrine | 1 | 2002 | 106 | 0.010 |
Why?
|
| Recurrence | 1 | 2004 | 655 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 852 | 0.010 |
Why?
|
| Acyl-CoA Oxidase | 1 | 2000 | 7 | 0.010 |
Why?
|
| Urban Health | 1 | 2001 | 40 | 0.010 |
Why?
|
| Coenzyme A Ligases | 1 | 2000 | 13 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2011 | 3150 | 0.010 |
Why?
|
| Oxidoreductases | 1 | 2000 | 58 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2000 | 182 | 0.010 |
Why?
|
| Length of Stay | 1 | 2004 | 826 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2001 | 100 | 0.010 |
Why?
|
| Frail Elderly | 1 | 2001 | 113 | 0.010 |
Why?
|
| Mitochondrial Proteins | 1 | 2000 | 108 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2000 | 151 | 0.010 |
Why?
|
| Incidence | 1 | 2003 | 1413 | 0.010 |
Why?
|
| Transfection | 1 | 2000 | 700 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2001 | 293 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2011 | 6831 | 0.010 |
Why?
|
| Prognosis | 1 | 2003 | 1775 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2001 | 798 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 1557 | 0.010 |
Why?
|
| Social Support | 1 | 2001 | 391 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2003 | 2059 | 0.010 |
Why?
|
| Cell Line | 1 | 2000 | 2036 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 2004 | 869 | 0.010 |
Why?
|
| Child | 1 | 2003 | 4614 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2000 | 1551 | 0.010 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 1990 | 45 | 0.000 |
Why?
|
| Thyrotropin | 1 | 1988 | 35 | 0.000 |
Why?
|
| Myocardial Infarction | 1 | 1990 | 918 | 0.000 |
Why?
|